IPM Take
Oncology spends enormous political energy on treating cancer after it appears. This dataset points upstream. HPV vaccination, hepatitis vaccination and treatment, H. pylori detection and eradication, and infection control are cancer interventions. The fact that the burden falls disproportionately on lower-resource settings makes prevention a precision-health and equity agenda, not just an infectious-disease agenda.
Executive Summary
A new IARC analysis published in The Lancet Oncology estimates that 2.3 million new cancer cases worldwide in 2024—about 12%, or one in eight—were attributable to infections. The assessment incorporated 12 infectious agents and updated infection–cancer relationships. Helicobacter pylori and HPV were the largest contributors, linked to roughly 760,000 and 750,000 cases, respectively. Hepatitis B, Epstein–Barr virus and hepatitis C were also major contributors, while the burden was disproportionately concentrated in lower-resource regions.
Why it matters
- Policymakers: Vaccination and infection treatment belong inside national cancer-control plans.
- Patients / advocates: Many infection-linked cancers are preventable before oncology treatment is ever needed.
- Public authorities: HPV, HBV and H. pylori programmes can be cancer-control infrastructure.
- Equity leaders: The global burden is heavily concentrated where prevention and early detection capacity are weakest.
Cancer is often discussed as though prevention means lifestyle.
Do not smoke. Drink less. Exercise. Screen.
This dataset widens the frame.
Around one in eight new cancers worldwide is attributable to infection. That is not a marginal corner of oncology. It is millions of diagnoses.
The policy implications are unusually concrete.
HPV can be vaccinated against. Hepatitis B can be vaccinated against. Hepatitis C can be treated. H. pylori can be detected and eradicated. Cervical precancer can be found and treated before invasive cancer develops.
These are not futuristic technologies.
Many already exist.
Which makes the inequality harder to defend.
The places carrying the highest infection-attributable cancer burden are often the same places where vaccination coverage, diagnostic infrastructure, screening and treatment access remain weakest.
That means the next breakthrough does not always need a new molecule.
Sometimes it needs procurement. A vaccine programme. A primary-care test. A laboratory. A functioning referral route.
Cancer policy likes breakthrough language because breakthroughs are visible.
Prevention is quieter.
It is also where millions of future cancers can still be stopped.
